Episode Details

BioNTech SE (BNTX) Q2 2026 — Reported Aug 4, 2026 pre-open for the three and six months ended June 30, 2026. Revenue EUR 105.6M, DOWN 59.5%. Net loss EUR 820.8M, more than DOUBLE the EUR 386.6M a year ago. FY2026 revenue guidance CUT from EUR 2.0-2.3B to EUR 1.6-1.9B. The ADR opened at $89.18, fell to $88.20, then reversed to $93.245 (+1.1%). ADS ratio 1:1; EUR/USD 1.1526. BioNTech cut 2026 revenue guidance by 400 million euros, doubled its quarterly loss, and wrote its COVID manufacturing equipment down to a recoverable value of ZERO - and the stock finished UP. That is not irrational: 80% of the market cap is net cash, so the whole 14-trial oncology pipeline is priced at about $4.6 billion. THE CALL: HOLD (3/5, THE CASH IS THE FLOOR - THE PIPELINE IS THE PRICE) — base-case value ~$79.0 vs ~$93.245 today. KEY METRICS: - CALL: HOLD 3/5 - fair value ~$79/ADS vs $93.245 (-15%). ADS RATIO 1:1 (the release states each ADS represents one ordinary share); EUR/USD 1.1526, cross-checked against the company's own Q2 buyback translation ($89.50 / EUR 77.85 = 1.1497). Vendor per-share data on ADRs is per-ADS in USD while the release is per-ordinary-share in EUR, so the P&L is rebuilt from the release; market cap from the cover page: 251,204,366 x $93.245 = $23,424M. - THE PRINT: revenue EUR 105.6M vs EUR 260.8M (-59.5%). Net loss EUR 820.8M vs EUR 386.6M. IFRS diluted LPS EUR (3.24) vs (1.60); adjusted EUR (2.22) vs (1.45). R&D EUR 551.0M (adjusted EUR 477.1M after EUR 73.9M of impairments). SG&A EUR 197.8M vs EUR 137.4M, +44%. - THE GUIDANCE CUT IS BIGGER THAN THE HEADLINE: FY26 revenue cut from EUR 2,000-2,300M to EUR 1,600-1,900M (-19% at the midpoint). H1 was EUR 223.7M, so the implied H2 is EUR 1,376-1,676M - and the company says the EUR 613M Bristol Myers Squibb collaboration revenue lands in Q3, i.e. 37-45% of the ENTIRE second half in one accounting entry. Strip it and the underlying business is guided to ~EUR 1.0-1.3B for the year. Reasons: softer COVID demand; Germany using existing inventory; a milestone slipping past 2026. - THE COVID FUNERAL: Q2 vaccine revenue EUR 51.9M vs EUR 153.3M (-66%), vs more than EUR 17B in 2022. For the FIRST time non-COVID revenue (EUR 53.7M) was the larger half. BioNTech capitalised the decline: EUR 87.0M of impairments at Marburg and Idar-Oberstein, of which EUR 68.9M of equipment had a recoverable amount 'determined to be zero'. Marburg is the plant it bought from Novartis in 2020 to make 750M doses a year. - VALUATION - SUM OF THE PARTS, NOT A DCF (no owner earnings to discount): cash and securities EUR 16,634.2M less EUR 316.1M of leases/loans = $18,808M = $74.87/ADS, 80% of the market cap (the 6-K also discloses BioNTech believes it is a PFIC). Charge the burn, ~$4.9B in PV to 2030, and you get $55.36/ADS. Add the risk-adjusted pipeline - pumitamig $2.8B (40% on a $6B peak, 50/50 with BMS), the ADCs and gotistobart $1.8B, residual COVID/mRNA/CureVac $1.5B = $24.28/ADS. Total $79.64; 25/50/25 weighting $79.07. REVERSE TEST: EV is ~$4,616M, so the price implies a $9,516M pipeline, 56% above what we carry. VS THE STREET: Buy, 21/3/0, avg $132.71 (low $96 - even that is ABOVE the price); they see +42%, we see -15%. We DIFFER and are more CAUTIOUS. CIK 0001776985. What to watch: Bullish: a clean DYNASTY-Breast02 readout in HER2-low breast cancer, due Q4 2026, moves us toward $105. Bearish: the EUR 613M BMS revenue not landing in Q3, or pumitamig's Phase 3 survival data failing to separate - either takes us to ~$58. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.